Trial 3C-23-8


An Open-Label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects with Relapsed, Refractory, or Newly Diagnosed Cancers

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Anti-Angiogenesis, Biological Response Modifier, Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Noureddine Miloud, D.M., Rabia Rehman, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Janet Luong, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.